MiR-29b拮抗多发性骨髓瘤驯化的树突状细胞促炎促肿瘤活性
研究分析六个miRNA谱数据集,发现miR-29b在正常成熟树突状细胞(DC)中上调、在肿瘤相关DC中显著下调,并在与多发性骨髓瘤(MM)细胞系共培养的原代DC及MM患者原代骨髓DC中验证。在共培养DC中强制表达miR-29b可抵消促炎通路及细胞因子/趋化因子信号网络,下调白细胞介素-23并拮抗Th17炎症反应,最终转化为对MM细胞的强抗增殖活性和基因组不稳定性降低。
要点
- miR-29b是正常成熟DC中上调、肿瘤相关DC中显著下调的唯一miRNA。
- 强制表达miR-29b可抵消DC中STAT3、NF-κB及细胞因子/趋化因子促炎通路。
- miR-29b下调白细胞介素-23并拮抗Th17炎症反应,抑制MM细胞增殖。
核心结论
- MM通过下调miR-29b重编程DC功能表型,恢复miR-29b可削弱DC支持MM细胞生长和存活的能力。
- 作者认为miR-29b是基于miRNA的MM免疫治疗的新颖且有吸引力的候选分子。
研究设计与样本
- 分析六个不同miRNA谱数据集,鉴定差异表达miRNA。
- 在与MM细胞系体外共培养的原代DC及MM患者原代骨髓DC中验证。
- 体外实验及SCID-synth-hu体内模型研究miR-29b功能。
主要发现
- miR-29b是正常成熟DC中上调、肿瘤相关DC中显著下调的唯一miRNA。
- 在与MM细胞共培养的DC中,强制表达miR-29b抵消STAT3和NF-κB及细胞因子/趋化因子信号网络,这些通路与患者不良预后和骨病发生相关。
- miR-29b在体外和SCID-synth-hu体内模型中下调白细胞介素-23,并拮抗Th17炎症反应。
- 上述效应转化为对MM细胞的强抗增殖活性和基因组不稳定性降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dendritic cells (DCs) have a key role in regulating tumor immunity, tumor cell growth and drug resistance. We hypothesized that multiple myeloma (MM) cells might recruit and reprogram DCs to a tumor-permissive phenotype by changes within their microRNA (miRNA) network. By analyzing six different miRNA-profiling data sets, miR-29b was identified as the only miRNA upregulated in normal mature DCs and significantly downregulated in tumor-associated DCs. This finding was validated in primary DCs co-cultured in vitro with MM cell lines and in primary bone marrow DCs from MM patients. In DCs co-cultured with MM cells, enforced expression of miR-29b counteracted pro-inflammatory pathways, including signal transducer and activator of transcription 3 and nuclear factor-κB, and cytokine/chemokine signaling networks, which correlated with patients' adverse prognosis and development of bone disease. Moreover, miR-29b downregulated interleukin-23 in vitro and in the SCID-synth-hu in vivo model, and antagonized a Th17 inflammatory response. All together, these effects translated into strong anti-proliferative activity and reduction of genomic instability of MM cells. Our study demonstrates that MM reprograms the DCs functional phenotype by downregulating miR-29b whose reconstitution impairs DCs ability to sustain MM cell growth and survival. These results underscore miR-29b as an innovative and attractive candidate for miRNA-based immune therapy of MM.
引用
- Botta C, Cucè M, Pitari MR, et al. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia. 2017. PMID: 29158557. doi:10.1038/leu.2017.336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。